Aug 12, 2022
Completed public equity offering with gross proceeds of $30 million Granted orphan medicinal product designation by the EMA for AT-007 for treatment of Galactosemia Continued progress in three registrational Phase 3 trials in areas of high unmet medical need, with multiple clinical milestones
May 19, 2022
NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will participate in
May 12, 2022
Continued progress in three Phase 3 trials in areas of high unmet medical need, with multiple clinical milestones expected in 2022 NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug
Displaying 1 - 10 of 15


Print Page
Email Alerts
RSS Feeds
Contact IR